Biosimulation Market Report 2018-2022: Focus on Application (Clinical Trials, PKPD, ADME), Delivery (Subscription, Ownership), End User (Biotech, Pharma Companies, Regulatory)

[junkie-button url=”” style=”grey” size=”medium” type=”round” target=”_blank”] HOME [/junkie-button]

The Biosimulation Market is expected to reach US$2.8 billion by 2022, from US$1.38 billion in 2017, at a CAGR of 15.9%.

The increase in R&D investments in the pharmaceutical and biotechnology industries, growing adoption of biosimulation software by regulatory bodies, technologically advanced QSP systems, need to curtail drug discovery and development costs, and growth in the biologics and biosimilars markets are driving the growth of the biosimulation market. On the other hand, market growth may be limited to a certain extent due to the lack of standardization for biosimulation solutions.

By product and service, the biosimulation market is segmented into software and services. The biosimulation services segment is projected to register the highest CAGR during the forecast period. The high growth in this segment is attributed to the recurring need for services such as data analysis and consulting services.

Based on the delivery model, the biosimulation market is segmented into ownership models and subscription models. The ownership models segment is expected to dominate the market during the forecast period; buyers mainly opt for these delivery models due to the associated security benefits.

In 2017, North America is expected to account for the largest share of the market, followed by Europe. However, Europe is expected to register the highest CAGR during the forecast period. The growing focus on research-related funding activities by governments is expected to assist in the development of the drug discovery and development process, thus driving the demand for biosimulation in the European region.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Biosimulation Market, By Product & Service

7 Biosimulation Market, By Application

8 Biosimulation Market, By Delivery Model

9 Biosimulation Market, By End User

10 Biosimulation Market, By Region

11 Competitive Landscape

12 Company Profiles

  • Advanced Chemistry Development
  • Certara
  • Chemical Computing Group
  • Dassault Systems
  • Evidera
  • Genedata
  • In Silico Biosciences
  • Inosim Software
  • Insilico Biotechnology
  • Leadinvent Technologies
  • Nuventra Pharma
  • Physiomics
  • Rosa
  • Schrdinger
  • Simulation Plus

For more information visit here.